文献速递妇科产科

阴道雌激素用于绝经后盆腔器官脱垂手术:多中心双盲随机安慰剂对照试验

Vaginal Oestrogen Therapy for Postmenopausal Women Undergoing Prolapse Surgery: A Multicentre Double-Blind Randomised Placebo-Controlled Clinical Trial.
PubMed 文献 · BJOG · 2026-08-28

荷兰22家医院的多中心双盲随机安慰剂对照试验纳入293例POP-Q≥2期、拟行初次自体组织脱垂修补的绝经后女性,术前4-6周至术后12个月使用阴道雌三醇乳膏(1 mg/g)或安慰剂。术后12个月雌三醇组92% vs 安慰剂组80%报告PGI-I改善(p=0.02),盆底相关生活质量更优(PFDI-20中位17 vs 25,p=0.03),不适/疼痛报告更少(EQ-5D-5L:61% vs 77%,p=0.04);解剖结局、复合手术成功、性功能及再干预率无差异。

要点

  • 围术期阴道雌三醇改善术后12个月患者报告结局和盆底相关生活质量。
  • 解剖结局、复合手术成功、性功能及再干预率两组无差异。
  • 可与绝经后初次脱垂手术女性共享决策时讨论阴道雌激素作为辅助治疗。

核心结论

  • 围术期阴道雌激素改善了术后12个月的患者报告结局和盆底相关生活质量,未影响解剖结局。
  • 研究结果支持在与接受初次脱垂手术的绝经后女性共享决策时讨论阴道雌激素作为辅助治疗选择。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,随访12个月。
  • 荷兰22家医院多中心开展。
  • 纳入POP-Q≥2期、拟行初次自体组织脱垂修补的绝经后女性。
  • 按1:1随机分配至阴道雌三醇乳膏(1 mg/g)或相同安慰剂,术前4-6周开始,持续至术后12个月(每周两次维持)。
  • 共293例女性参与,57例退出。

主要发现

  • 术后12个月,雌三醇组92% vs 安慰剂组80%报告PGI-I量表改善(p=0.02)。
  • 雌三醇组盆底相关生活质量更好(PFDI-20中位评分17 vs 25,p=0.03)。
  • 雌三醇组报告不适/疼痛的女性更少(EQ-5D-5L:61% vs 77%,p=0.04)。
  • 解剖结局、复合手术成功、性功能及再干预率两组无差异。
  • 乳膏易于使用;若提供有意义的健康获益,80%会使用1年。

关键数值与推荐

  • 主要结局为术后12个月脱垂症状主观改善,定义为PGI-I量表「much」或「very much」改善。
  • 阴道雌三醇乳膏浓度1 mg/g,术前4-6周开始,术后每周两次维持至12个月。

临床怎么用

  • 对于接受初次自体组织脱垂修补的绝经后女性,可讨论围术期使用阴道雌三醇作为辅助治疗以改善患者报告结局和生活质量。
  • 需告知患者阴道雌激素未显示解剖结局、复合手术成功、性功能或再干预率的改善。

局限性

  • 293例参与中57例退出,可能影响结果解释。
  • 随访12个月,缺乏更长期数据。
  • 研究在荷兰22家医院开展,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether vaginal oestrogen therapy improves outcomes after prolapse surgery in postmenopausal women. DESIGN: Double-blind, randomised, placebo-controlled trial with 12 month follow-up. SETTING: Multicentre, 22 hospitals in the Netherlands. POPULATION: Postmenopausal women with POP-Q stage ≥ 2 scheduled for primary native-tissue prolapse repair. METHODS: Women were randomised (1:1) to vaginal oestriol cream (1 mg/g) or identical placebo, started 4-6 weeks preoperatively and continued to 12 months postoperatively (twice-weekly maintenance). MAIN OUTCOME MEASURE: Subjective improvement in prolapse symptoms at 12 months postoperatively, defined as "much" or "very much" improved on the Patient Global Impression of Improvement (PGI-I) scale. RESULTS: In total 293 women participated, 57 women dropped out. At 12 months, 92% of women in the oestrogen group versus 80% in the placebo group reported improvement on the PGI-I scale (p = 0.02). Pelvic floor-related quality of life was better in the oestrogen group (median score PFDI-20: 17 vs. 25, p = 0.03), and fewer women reported discomfort/pain (EQ-5D-5L: 61% vs. 77%, p = 0.04). Anatomical outcomes, composite surgical success, sexual function and reintervention rates did not differ between groups. The cream was easy to use; 80% would use it for 1 year if it provided meaningful health benefits. CONCLUSIONS: Perioperative vaginal oestrogen improved patient-reported outcomes and pelvic floor-related quality of life at 12 months, without affecting anatomical outcomes. These findings support discussing vaginal oestrogen as an adjunctive treatment option in shared decision-making with postmenopausal women undergoing primary prolapse surgery. TRIAL REGISTRATION: NL-OMON55535, https://www.onderzoekmetmensen.nl/en/trial/55535.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Vodegel EV, van Rest K, Speksnijder L, et al. Vaginal Oestrogen Therapy for Postmenopausal Women Undergoing Prolapse Surgery: A Multicentre Double-Blind Randomised Placebo-Controlled Clinical Trial. BJOG. 2026. PMID: 42663275. doi:10.1111/1471-0528.70311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。